01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan #ORPH – First volunteer dosed in intranasal COVID-19 vaccine clinical trial January 11, 2021 – Posted in: Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that the first volunteer has been dosed with the Codagenix Inc. (“Codagenix”) needle free, intranasal COVID-19 vaccine, COVI-VAC. Conducted by hVIVO, part of Open Orphan plc, the Phase I clinical trial of COVI-VAC is being carried out at their facility in the UK. COVI-VAC is a single-dose, intranasal, live…

Continue reading

Open Orphan #ORPH – MHRA approval for nasal COVID-19 vaccine clinical trial – Posted in: Uncategorized

First in human trials for vaccine candidate with the potential to confer long-term immunity Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, announces the first in human (Phase I) study of Codagenix intranasal SARS-CoV-2 (COVID-19) vaccine candidate has received approval from the UK’s independent Medicines and Healthcare Products Regulatory Agency (MHRA). Further to the…

Continue reading

Open Orphan #ORPH Awarded Contract From Codagenix Inc For COVID-19 Vaccine Trial July 27, 2020 – Posted in: Open Orphan (ORPH), Uncategorized

Tuesday 28th July, 2020 Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. (“Codagenix”) to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers.   Highlights: First in human…

Continue reading